A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts

被引：0

作者：

Thomas, S. ^{[1
]}

Doebele, R. C. ^{[2
]}

Spigel, D. ^{[3
]}

Tehfe, M. ^{[4
]}

Reck, M. ^{[5
]}

Verma, S. ^{[6
]}

Zimmermann, A. ^{[7
]}

Alexandris, E.

Lee, P. ^{[8
]}

Bonomi, P. ^{[9
]}

机构：

[1] Univ Calif San Francisco Fresno, Fresno, CA USA

[2] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[5] German Ctr Lung Res DZL, Lung Clin Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany

[6] Univ Calgary, Calgary, AB, Canada

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Eli Lilly & Co, Bridgewater, NJ USA

[9] Rush Univ, Med Ctr, Chicago, IL 60612 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

119P

引用

页数：2